SeaStar Medical (ICU) Q2 2026 Earnings Call Transcript
SeaStar Medical Holding Corp (ICU) reported Q2 2026 net revenue of $615,000, up 82% year over year, and six-month net revenue of $1.1 million. Gross margin was 91%. Net loss was $3.7 million ($0.91/share). Cash was $7.0 million at June 30, 2026. QUELIMMUNE adoption reached 20 hospitals; NEUTRALIZE-AKI enrolled 223/339 patients.
How this was made
The 30-second read
Why it matters
Traders can update models for revenue trajectory, hospital adoption pace, and clinical enrollment risk, while also reassessing liquidity risk given the decline in cash and ongoing net losses.
Market read
Fresh Q2 financial datapoints and trial enrollment metrics, plus a stated ICD-10-PCS implementation date and modular PMA timeline, create actionable updates for near-term risk and expectation setting.
What to watch
The transcript emphasizes operational targets (25 hospitals by year-end, PMA late 2027) but does not provide updated guidance on funding needs or detailed cost trajectory beyond R&D and G&A increases, which could drive risk pricing.
Background
SeaStar Medical Holding Corporation (ICU) held its Q2 2026 earnings call focused on QUELIMMUNE commercialization and the NEUTRALIZE-AKI pivotal trial progress.
Ticker impact
SeaStar Medical reported Q2 2026 net revenue of $615,000 (+82% YoY) and updated NEUTRALIZE-AKI enrollment to 223/339.
Moderately positive bias, with volatility likely around cash runway and the slower-than-desired enrollment pace.
Revenue growth and doubling hospital customer base are supportive, but the company also disclosed slower monthly enrollment (8 to 12 vs expected 15 to 20) and reduced cash ($7.0M vs $12.0M), which can temper sentiment.
Market effects
Highlights adoption and PMA modular strategy for a Class III device, which may influence sentiment toward other early-stage medtech with FDA pathway optionality.
No clear regional-specific impact beyond US pediatric critical care adoption.
Primarily US FDA and hospital adoption dynamics; limited direct global read-through.
Counterpoint
Despite strong reported revenue growth, the company’s cash balance fell materially and enrollment is slower than desired, so the market may discount commercialization momentum until pivotal trial milestones accelerate.
Key entities
- companySeaStar Medical Holding Corporation
Subject of the earnings call transcript, reporting Q2 2026 financials and clinical and commercial progress for QUELIMMUNE and NEUTRALIZE-AKI.
- productQUELIMMUNE
Proprietary SCD therapy brand for pediatric patients, discussed in terms of hospital adoption and revenue growth.
- clinical_programNEUTRALIZE-AKI
Pivotal trial for adult patients, with enrollment and endpoint details provided.
- regulatorFDA
Regulatory body referenced for modular PMA submission timing and the SAVE safety registry.
